Daniel Canter

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety et al. · The Lancet Oncology · 2020 · 442 citations · Full text

Medicine, Oncology, Urology +13

Too Frail for Surgery? Initial Results of a Large Multidisciplinary Prospective Study Examining Preoperative Variables Predictive of Poor Surgical Outcomes

Louis M. Revenig, Daniel Canter, Maxwell D. Taylor et al. · Journal of the American College of Surgeons · 2013 · 308 citations

Medicine, Perioperative Medicine, Surgery +16

Objective Measures of Renal Mass Anatomic Complexity Predict Rates of Major Complications Following Partial Nephrectomy

Jay Simhan, Marc C. Smaldone, Kevin Tsai et al. · European Urology · 2011 · 277 citations · Full text

Medicine, Nephrology, Surgery +11

Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score

Alexander Kutikov, Marc C. Smaldone, Brian L. Egleston et al. · European Urology · 2011 · 268 citations

Medicine, Oncology, Pathology +17

Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study

Neal D. Shore, Stephen A. Boorjian, Daniel Canter et al. · Journal of Clinical Oncology · 2017 · 172 citations · Full text

Medicine, Oncology, Urology +17